AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

AbbVie Inc.’s stock rose 7.7% Friday to lead ... delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Skyrizi, Rinvoq sales expected to surpass $31 billion by 2027 Humira sales decline 49% due to cheaper biosimilar competitors AbbVie earns $2.16 per share in Q4, beats estimates Jan 31 (Reuters ...

For most of those years, AbbVie enjoyed lucrative success with Humira. However, the company's revenue has dipped since Humira lost patent exclusivity in 2023, and the stock price has only ...